Plain-English translation of NCT07198659 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-phase trial is testing a new approach called NeuMed, which uses your own white blood cells (neutrophils) collected from your blood. These cells are treated in a laboratory and loaded with Monomethyl Auristatin E (MMAE), a cancer-fighting drug, then put back into your body to attack pancreatic cancer. The goal is to see if this treatment is safe and whether it can help slow or stop cancer growth.
Pancreatic cancer that cannot be surgically removed is very difficult to treat, and current therapies don't work well for all patients. This trial explores whether using your body's own immune cells as a delivery system for anti-cancer drugs might offer a new option for people like you.
You likely qualify if…
You likely don't qualify if…
Your participation involves having blood drawn so doctors can isolate and prepare your immune cells in a laboratory over several weeks. Before receiving the treatment back, you'll receive a focused radiation therapy to your pancreatic cancer. Then your prepared cells—loaded with the medication—will be infused back into your body. You'll need to visit the hospital for these procedures and likely for follow-up visits to monitor your safety and how you're responding.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China